» Articles » PMID: 37927962

Inflammation and Coagulation Are Two Interconnected Pathophysiological Pathways in Atrial Fibrillation Pathogenesis

Overview
Journal J Inflamm Res
Publisher Dove Medical Press
Date 2023 Nov 6
PMID 37927962
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Atrial fibrillation (AF) is associated with elevated levels of clotting factors such as tissue factor (TF) and factor XII (FXII). Various inflammation markers, such as interleukin-6 (IL-6), tumor necrosis factor-α (TNF- α), and high-sensitive C-reactive protein (hs-CRP), have also been associated with AF. This study explores the relationship between inflammation markers and coagulation activity, including their impact on heart structural changes in these patients.

Methods: We observed 283 patients with nonvalvular AF who underwent a complete examination at admission, but only 183 patients have successful cardioversion. As a control group, similar patients without AF were examined. The markers of the coagulation and inflammation were studied by ELISA on the analyzer "Stat Fax 303 Plus". Studies were conducted using l statistical package SPSS 13.0.

Results: It was revealed that patients with AF had significantly higher levels of hs-CRP, IL-6, and TNF-α and had elevated levels of TF and FXII compared with control group. The moderate correlations were observed between IL-6 and left atrial diameter (LAD), IL-6 and LA stiffness, hs-CRP and left atrial volume (LAV), TF and LAV.

Conclusion: We have demonstrated that patients with AF have the relationship between elevated levels of inflammatory markers and coagulation activity, which contributes to structural atrial remodeling.

Citing Articles

The Neutrophil-to-Lymphocyte Ratio Is an Independent Inflammatory Biomarker for Adverse Events in Patients With Atrial Fibrillation: Insights From the Murcia AF Project II (MAFP-II) Cohort Study.

Soler-Espejo E, Marin F, Lopez-Galvez R, Ramos-Bratos M, Sanchez-Villalobos M, Esteve-Pastor M Clin Cardiol. 2025; 48(2):e70102.

PMID: 39985306 PMC: 11845907. DOI: 10.1002/clc.70102.


Pathophysiology, molecular mechanisms, and genetics of atrial fibrillation.

Han P, Zhao X, Li X, Geng J, Ni S, Li Q Hum Cell. 2024; 38(1):14.

PMID: 39505800 DOI: 10.1007/s13577-024-01145-z.


Cardiac macrophages in maintaining heart homeostasis and regulating ventricular remodeling of heart diseases.

Kang M, Jia H, Feng M, Ren H, Gao J, Liu Y Front Immunol. 2024; 15:1467089.

PMID: 39372400 PMC: 11449765. DOI: 10.3389/fimmu.2024.1467089.


Global epidemiology of mental disorder in atrial fibrillation between 1998-2021: A systematic review and meta-analysis.

Zhang S, Zhang N, Liu L, Zheng W, Ma Z, Qiao S World J Psychiatry. 2024; 14(1):179-193.

PMID: 38327890 PMC: 10845231. DOI: 10.5498/wjp.v14.i1.179.

References
1.
Su J, Luo M, Liang N, Gong S, Chen W, Huang W . Interleukin-6: A Novel Target for Cardio-Cerebrovascular Diseases. Front Pharmacol. 2021; 12:745061. PMC: 8421530. DOI: 10.3389/fphar.2021.745061. View

2.
Li X, Peng S, Wu X, Guan B, Tse G, Chen S . C-reactive protein and atrial fibrillation: Insights from epidemiological and Mendelian randomization studies. Nutr Metab Cardiovasc Dis. 2022; 32(6):1519-1527. DOI: 10.1016/j.numecd.2022.03.008. View

3.
Guzel T, Kis M, Senoz O . The correlation between the left atrial volume index and atrial fibrillation development in heart failure with mildly reduced ejection fraction and long-term follow-up results. Acta Cardiol. 2022; 77(7):647-654. DOI: 10.1080/00015385.2022.2067674. View

4.
Fontes J, Rose N, cihakova D . The varying faces of IL-6: From cardiac protection to cardiac failure. Cytokine. 2015; 74(1):62-8. PMC: 4677779. DOI: 10.1016/j.cyto.2014.12.024. View

5.
Yau J, Teoh H, Verma S . Endothelial cell control of thrombosis. BMC Cardiovasc Disord. 2015; 15:130. PMC: 4617895. DOI: 10.1186/s12872-015-0124-z. View